D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.
Philip C. Mack,Mary W. Redman,James C. Moon,Sarah B. Goldberg,Roy S. Herbst,Mary Ann Melnick,Zenta Walther,Fred R. Hirsch,Katerina Politi,Karen Kelly,David R. Gandara +10 more
TL;DR: CtDNA from patient plasma has demonstrated diagnostic utility in non-small cell lung cancer (NSCLC) and longitudinal changes in mutant allele frequency (MAF) have great potential to re-expression in patients with NSCLC.
Journal ArticleDOI
A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
Anthony B. El-Khoueiry,Robert T. O'Donnell,Thomas J. Semrad,Philip C. Mack,Suzette Blanchard,Nathan Bahary,Yixing Jiang,Yun Yen,John J. Wright,Helen X. Chen,Heinz-Josef Lenz,David R. Gandara +11 more
TL;DR: While the combination of cixutumumab and sorafenib had a toxicity profile similar to that of sorAFenib monotherapy, it manifested limited clinical efficacy in unselected patients with HCC.
Journal ArticleDOI
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
Robert J. Morgan,Timothy W. Synold,David R. Gandara,Franco M. Muggia,Sidney A. Scudder,Eddie Reed,Kim Margolin,James Raschko,Lucille Leong,Stephen Shibata,Merry Tetef,Steven A. Vasilev,Kathryn F. McGonigle,Jeffrey Longmate,Yun Yen,Warren Chow,George Somlo,Mary Carroll,James H. Doroshow +18 more
TL;DR: Estimating the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN) in recurrent ovarian cancer (OC) and measuring their effects on CBDCA pharmacokinetics concluded that Steady-state levels of >1 μg/mL CSA (HPLC assay) are achievable in vivo.
Journal ArticleDOI
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations
Christian Caglevic,Christian Rolfo,Ignacio Gil-Bazo,Andrés F. Cardona,Jorge Sapunar,Fred R. Hirsch,David R. Gandara,Gilberto Morgan,Silvia Novello,Marina Chiara Garassino,Giannis Mountzios,Natasha B. Leighl,Denisse Bretel,Oscar Arrieta,Alfredo Addeo,Stephen V. Liu,Luis Corrales,Vivek Subbiah,Francisco Aboitiz,Franz Villarroel-Espindola,Felipe Reyes-Cosmelli,Ricardo Morales,Mauricio Mahave,Luis E. Raez,Jorge A. Alatorre,Edgardo S. Santos,Luis Ubillos,Daniel Sw Tan,Christoph C. Zielinski +28 more
TL;DR: It is projected that a modest delay in care of only 4 months for five prevalent types of cancer will lead to an excess of over 3,600 cancer deaths in the subsequent years.
Journal ArticleDOI
Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).
John V. Heymach,Bonnie S. Glisson,Robert C. Doebele,C. Huang,David R. Gandara,S. Le Scouiller,Marcelo Marotti,D.R. Camidge +7 more
TL;DR: This study assessed cediranib plus EP as first-line therapy for extensive stage/metastatic lung cancer and found the dose was deemed tolerable and 12 additional pts recruited to an expanded cohort.